The core therapeutic purpose of this medicine, a fixed-dose combination, is commonly used for managing symptoms related to smooth muscle spasm in the gastrointestinal tract. This dual-action formulation is commonly used across conditions presenting with acute episodes of digestive distress in pediatric patients, including Infantile Colic and Irritable Bowel Syndrome (IBS) symptoms. The antispasmodic component may assist with symptoms related to heightened physiological activity, such as spasms in the gastrointestinal tract.

The medicine helps address symptom clusters that may become intense or disruptive, specifically focusing on painful muscle spasms, abdominal cramping, bloating, and flatulence. Applied during phases of increased distress, it provides support that contributes to easing the overall symptom load of intestinal pressure and spasms. The dual action helps patients cope more steadily with difficult episodes. This combination is commonly used to provide symptomatic assistance when both cramping and gas interfere with daily comfort.

---

Quick Fact: Supportive Assistance for Dual Gastrointestinal Discomfort

Symptom Domain	General Therapeutic Benefit
Spasmodic Pain / Cramping	Helps support a more manageable experience of acute discomfort.
Intestinal Gas / Bloating	Contributes to easing the overall symptom load of internal pressure.
Common Use Context	Acute episodes of functional digestive upset in young children.

---

This section outlines the official eligibility and contraindication information for Meftal-Spas DPS (Mefenamic Acid and Dicyclomine Hydrochloride), based strictly on regulatory documents.

---

Eligibility and Contraindications

Classification	Populations/Conditions
Contraindicated	Patients with a known hypersensitivity to the drug or any other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The medicine is also strictly prohibited for individuals with active ulceration or chronic inflammation of the upper or lower gastrointestinal tract, and those with pre-existing renal disease or obstructive uropathy.
Use Not Recommended	Pregnancy, particularly the third trimester (due to risks to the fetus and labor). It is also not recommended for nursing mothers due to potential serious adverse reactions in the infant.
Special Caution Required	The medicine should be used with caution in elderly patients (65 years and older) and those with impaired liver function, heart disease (such as heart failure or hypertension), glaucoma, prostate hypertrophy, or a history of asthma or aspirin-sensitive asthma.
Age Restrictions	The tablet formulation is generally not recommended for use in children below 12 years of age, and is contraindicated for infants below six months.

---

Regulatory Basis: Official regulatory documents clearly define who must not use this medicine (contraindications) and for whom use is not recommended, focusing on preventing severe allergic reactions, minimizing the risk of gastrointestinal bleeding/perforation, and protecting vulnerable populations like pregnant women and infants.

Meftal-Spas DPS, a combination of mefenamic acid (a Non-Steroidal Anti-Inflammatory Drug or NSAID) and dicyclomine (an anticholinergic), can interact with several other medications. It is essential to inform your doctor or pharmacist about all prescription, over-the-counter drugs, vitamins, and herbal supplements you are taking.

Increased Bleeding Risk (Mefenamic Acid Component)

Combining this medication with drugs that affect blood clotting can increase the risk of serious gastrointestinal bleeding and hemorrhage. Avoid or use with close monitoring:

• Anticoagulants (blood thinners) like warfarin.
• Antiplatelet drugs such as aspirin (low-dose for cardiac protection may be affected).
• Other NSAIDs (e.g., ibuprofen, naproxen) or COX-2 inhibitors.
• Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs).

Effect on Blood Pressure and Kidney Function

The mefenamic acid component can reduce the effectiveness of several antihypertensive drugs (blood pressure medications) and diuretics (water pills). Concomitant use with ACE inhibitors, Angiotensin Receptor Blockers (ARBs), or diuretics, especially in older or dehydrated patients, may increase the risk of kidney function deterioration or acute renal failure. Drugs like lithium and methotrexate may have increased blood levels, leading to toxicity, when taken with mefenamic acid.

️‍️ Increased Anticholinergic Side Effects (Dicyclomine Component)

Using dicyclomine with other medicines that also have anticholinergic properties can lead to additive side effects like increased drowsiness, dry mouth, blurred vision, difficulty urinating, or constipation. This includes some antipsychotics, tricyclic antidepressants, and certain medications for Overactive Bladder (OAB). Dicyclomine may also interfere with the absorption of certain drugs, such as digoxin, and can counteract the effects of medications that improve gastrointestinal motility (like metoclopramide).

How Meftal-Spas DPS Works

The drug's mechanism involves the distinct pharmacodynamic actions of its two components: Dicyclomine and Mefenamic Acid.

Dicyclomine is an anticholinergic agent that functions as a specific antagonist of muscarinic acetylcholine receptors. This interaction decreases the binding of acetylcholine at postganglionic parasympathetic nerve endings. The resulting reduction in cholinergic activity leads to a relaxation and decreased contractile force in the smooth muscle of the gastrointestinal tract.

Mefenamic Acid is a non-steroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition blocks the enzymatic conversion of arachidonic acid into pro-inflammatory and algogenic prostaglandins. The resulting decrease in prostaglandin synthesis reduces localized modulation of pain and inflammatory pathways.

How to Use Meftal-Spas DPS — Official Administration Guidelines

Meftal-Spas DPS is administered according to standardized dosage and administration instructions. These guidelines establish the method for taking the medicine.

Administration Details

Guideline Element	Instruction
Route of Administration	Oral route (swallowing the tablet)
Standard Dosage Form	Uncoated tablet containing Mefenamic Acid 250 mg and Dicyclomine Hydrochloride 10 mg
Dosing Schedule (Adults/Adolescents)	1 to 2 tablets per dose
Frequency	Up to three times daily
Timing Relative to Meals	Should be taken preferably with or after food

Constraints and Special Instructions

Standard instructions impose limits on the duration of use to ensure proper administration. The total course of therapy must not exceed 7 days at a time. The total daily dose of Mefenamic Acid in any formulation (including Double Strength) should not exceed 1500 mg.

Population-Specific Use

For elderly patients, administration must be managed with caution, and an appropriate dose reduction is indicated to ensure correct use of the medicine. There are no specific instructions documented regarding steps to take for a missed dose in the reviewed clinical documentation.

Research Evidence / Overview of Studies for Meftal-Spas DPS

Evidence for Use in Infantile Colic

The primary area of research involved studies that examined the components of this oral suspension in infants presenting with colic. This clinical context is characterized by conditions involving periods of heightened symptoms and frequent acute or disruptive episodes. Research has primarily focused on the evaluation of the individual active ingredients, Dicycloverine and Simethicone, in this specific age group.

The research primarily relied upon short-term Randomized Controlled Trials (RCTs). Researchers applied these trials in studies conducted during periods of increased symptom activity, observing infants, generally those under six months of age, who were experiencing colic. Researchers monitored daily crying time and patient-reported outcomes describing perceived discomfort during the study period.

---

Component 1: Dicycloverine (Antispasmodic) Research Focus

For the antispasmodic component, Dicycloverine, studies explored outcomes reflecting daily functioning or activity level, such as the duration of crying. Studies reported observations of daily crying time in the studied infant populations. The available evidence, largely from older sources, has been broadly classified as evidence suggests a moderate level of insight into the component’s use in this context. Reported outcomes were generally based on short-term observation periods (less than a month).

Component 2: Simethicone (Antiflatulent) Research Focus

For the antiflatulent component, Simethicone, research also involved short-term Randomized Controlled Trials with infants experiencing colic. The studies explored outcomes describing episodic or acute changes related to physical discomfort, such as bloating and gas. Studies reported that findings were mixed across many of these studies. This led to the evidence being classified as having a low certainty in scientific reviews for its use in this context.

---

Evidence for Related Gastrointestinal Symptoms (Antispasmodic Component)

The Dicycloverine component was studied for outcomes related to physical discomfort in conditions characterized by smooth muscle spasm and presenting with cycles of stability and flare-ups, such as Irritable Bowel Syndrome (IBS) in adults. Findings describe patterns observed in these studies related to outcomes related to physical discomfort, but the evidence specific to Dicycloverine is often derived from older, limited studies.

Gaps, Limitations, and Unanswered Research Questions

Scientific reviews highlight several key areas where the evidence for this combination medicine remains insufficient or uncertain. A central limitation is the lack of comparative evidence from high-quality trials evaluating the specific fixed-dose combination of Dicycloverine and Simethicone against placebo in the targeted pediatric population.

Furthermore, much of the supportive research is considered dated. The follow-up durations were limited in nearly all studies. Consequently, long-term effects are not fully established, and there is limited information about the progression of symptoms over time in children who receive this treatment. This research provides context but research does not determine whether an individual will respond similarly.

Common questions about Meftal-Spas DPS (FAQ)

---

Q: What should I do if I miss a dose of Meftal-Spas DPS?

According to official regulatory documents, if a dose is missed, official guidance typically states that it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the general recommendation is to skip the missed dose and resume the regular schedule. Official guidance states that a double dose should not be taken to make up for one that was missed.

---

Q: Is Meftal-Spas DPS safe to take during pregnancy or while breastfeeding?

Official information indicates that the Mefenamic Acid component of this medicine is contraindicated, or prohibited, during the third trimester of pregnancy due to risks to the fetus. Use during the first and second trimesters requires caution. For breastfeeding, due to the potential for serious adverse reactions in the infant, a healthcare provider may advise discontinuing nursing or discontinuing the drug.

---

Q: What are the signs of an allergic reaction to Meftal-Spas DPS?

Signs of a serious allergic reaction, as documented for the active ingredients, may include swelling of the face, eyes, lips, or tongue, difficulty breathing, or hives (itchy, raised patches of skin). Some severe drug reactions can also affect internal organs, which may present as fever, swollen glands, or yellowing of the skin or eyes. If these signs are observed, patients are typically advised to seek emergency medical care.

---

Q: How should I store the Meftal-Spas DPS tablets?

Regulatory guidance for the Meftal-Spas tablets specifies that they should be stored at room temperature and kept away from direct heat, light, and excessive moisture. For safety, the medicine should be kept out of the reach and sight of children.

---

Q: Is it safe to drink alcohol while taking Meftal-Spas DPS?

Official product information generally states that alcohol should be avoided while taking this medication. This is because alcohol consumption can increase the risk of serious side effects like gastrointestinal bleeding. It may also worsen central nervous system effects such as drowsiness and dizziness caused by the Dicyclomine component.

---

Q: How do I dispose of expired or unused Meftal-Spas DPS tablets?

General regulatory guidelines for drug disposal state that expired or unused tablets should not be disposed of in household trash or flushed down the toilet. The recommended practice is to return the medication to a local pharmacy, hospital, or drug take-back program for safe and proper disposal, following local pharmaceutical waste regulations.

Storage and Disposal of Meftal-Spas DPS

The storage of Dicycloverine and Simethicone oral suspension must comply strictly with the conditions defined in the official regulatory labeling to ensure product stability.

Requirement	Condition
Temperature	Store below 25°C
Prohibited Environment	Protect from freezing
Environmental Protection	Store in a dry place and protect from light
Container Rule	Keep in the original container
Child Safety	Store out of the sight and reach of children

The official labeling mandates that the product must not be disposed of using household waste or wastewater. Any unused or expired Meftal-Spas DPS must be discarded in accordance with specific local pharmaceutical waste regulations.